Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

An Autopsy of the Clinical Reasoning Process.

Acta clinica Belgica·2016
Same author

Panel-reactive screening and treatment practices following bridge to transplantation ventricular assist device placement.

Transplantation proceedings·2009
Same author

Computer-interpretable clinical practice guidelines. Where are we and where are we going ?

Yearbook of medical informatics·2006
Same author

Autologous transfusion -- a reasonable measure under the principles of health economics?

Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS·2003
Same author

Health economics of contraception.

Obstetrics and gynecology clinics of North America·2000
Same author

The cost-effectiveness of autologous transfusion revisited: implications of an increased risk of bacterial infection with allogeneic transfusion.

Transfusion·1999

相关实验视频

Updated: Jun 23, 2026

Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

最佳的医疗疗法优于移植治疗I,II和III类心力衰竭:一个决策分析方法.

R S Freudenberger1, J Kim, I Tawfik

  • 1University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ, USA. freuders@umdnj.edu

Circulation
|July 6, 2006
PubMed
概括
此摘要是机器生成的。

在I,II和III类心力衰竭中,最佳医疗疗 (OMT) 提供了比心脏移植 (HT) 更大的生存益处. 心脏移植在IV类中优越,但未来的进展可能会改变这些发现.

更多相关视频

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft
08:30

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft

Published on: February 14, 2022

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment
08:49

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment

Published on: August 2, 2024

相关实验视频

Last Updated: Jun 23, 2026

Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft
08:30

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft

Published on: February 14, 2022

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment
08:49

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment

Published on: August 2, 2024

科学领域:

  • 心脏病学 心脏病学
  • 移植医学 移植医学
  • 卫生经济学 卫生经济学

背景情况:

  • 心脏移植 (HT) 与最佳医疗疗 (OMT) 的比较生存益处仍然没有量化.
  • 心力衰竭 (HF) 管理策略需要对不同疾病严重程度进行基于证据的比较.

研究的目的:

  • 模拟和比较纽约心脏协会 (NYHA) 功能类的OMT与HT的长期生存结果.
  • 为了为临床决策提供有关晚期心力衰竭最佳治疗策略的信息.

主要方法:

  • 开发了一个模拟随机临床试验的决策分析模型.
  • 年度OMT死亡率基于已确定的临床试验数据 (MERIT-HF,COPERNICUS).
  • 根据历史生存数据 (1982-2001) 来得出HT死亡率.

主要成果:

  • 在NYHA类I,II和III中,OMT的预期寿命高于HT,分别为113个月,38个月和6个月.
  • 在NYHA IV类患者中,HT显示了26个月的生存优势,而不是OMT.
  • 敏感性分析表明,潜在的等价性与OMT或HT生存率的具体改善.

结论:

  • 目前的OMT为NYHA类I-III提供了优越的生存率,与HT相比.
  • 根据目前的数据,HT是NYHA IV级心力衰竭的首选治疗方法.
  • 未来OMT或HT的进步可能会改变它们相对收益的平衡.